Data Sheet

Product Name:	LR-90
Cat. No.:	CS-M0920
CAS No.:	245075-84-7
Molecular Formula:	$C_{35}H_{34}Cl_2N_4O_8$
Molecular Weight:	709.57
Target:	COX
Pathway:	Immunology/Inflammation
Solubility:	DMSO : ≥ 100 mg/mL



BIOLOGICAL ACTIVITY:

LR-90 is an **advanced glycation end product (AGE)** inhibitor, inhibits inflammatory responses in human monocytes[1]. LR-90 is also used in the research of diabetic animal model[2]. IC50 & Target: AGE[1] ***In Vitro:*** LR-90 (0, 25, 50, 100, and 200 μM) inhibits RAGE, MCP-1, COX-2, IP-10 and NOX2 mRNA expression in THP-1 cells in a dose-dependent manner, after pretreatment 1 h befor S100b stimulatation for 4 hours[1].

LR-90 (0, 25, 50, 100, and 200 μM) dose-dependently and significantly blocks THP-1 cells adherence to endothelial cells after pretreatment 1 h befor S100b stimulatation for 24 hours[1].

LR-90 (0, 25, 50, 100, and 200 μM, for 24 hours) shows no effect on the cell viability of THP-1 cells[1]. ***In Vivo:*** LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats[2].

LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2].

References:

[1]. Figarola JL, et al. Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes. 2007 Mar;56(3):647-55.

[2]. Figarola JL, et al. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia. 2008 May;51(5):882-91.

CAIndexNames:

Propanoic acid, 2,2'-[methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methyl-

SMILES:

O=C(NC1=CC=C(C=C1)OC(C)(C)C(O)=O)NC(C(Cl)=C2)=CC=C2CC3=CC=C(C(Cl)=C3)NC(NC4=CC=C(C=C4)OC(C)(C)C(O)=O)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com
Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA